A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 487 participants.
Also called NCT06952530
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 487 participants
- Sponsor
- Registry
-
NCT06952530
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06952530. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- Condition
- Hypertension
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06952530- Content hash
a0fecfcbc50ec04d0589be4bb96ad88728e0f56f04d6308f242411ff150fd83c